8 results about "ALDH2" patented technology

The invention relates to the technical field of medical preparations, and discloses application of HMB (beta-hydroxy-beta-methylbutyric acid) or an HMB-containing substance in preparation of a medicine for preventing and / or relieving alcohol hangover and / or relieving acute alcoholic liver injury. The substance containing HMB comprises calcium beta-hydroxy-beta-methylbutyrate (CaHMB), the CaHMB can significantly improve the tolerance of acute alcohol exposure and improve damaged exercise coordination, and the CaHMB can reduce the content of ethanol in serum and accelerate the change process of acetaldehyde in the serum; meanwhile, CaHMB can enhance the activity of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH2) in the liver and accelerate the alcohol metabolism process; besides, the CaHMB can reduce the levels of ALT and AST in serum, relieve liver inflammation caused by alcohol, effectively relieve liver injury and achieve the effects of dispelling the effects of alcohol and protecting the liver.

The invention relates to a method for diagnosing Pitt-Hopkins Syndrome (PTHS) using a single test, which comprises the steps of: a) providing an isolated biological sample; b) extracting and processing nucleic acids from the isolated biological sample; c) carrying out real-time PCR (qPCR) analysis on the extracted and processed sample; d) determining in the biological sample, using qPCR, the expression level of at least 4 of 13 genes selected according to the calculation of the number of copies; e) analysing the expression levels of the genes using machine learning; and f) determining the presence of PTHS according to the result obtained from at least four genes, wherein the 4-13 genes are selected from the group consisting of GLRA1, GLRA2, GLRA3, TCF4, ALDH1, ALDH2, RXRG1, APOD, OXTR, S1PR5, LPAR1, CHRM4 and GRIN2A.

The application discloses a class of acetaldehyde dehydrogenase 2 (ALDH2) agonists, and a preparation method and application thereof. Specifically, the application provides a compound or stereoisomers, optical isomers, non-racemic or racemic thereof, or a pharmaceutically acceptable salt thereof, or a solvate or N-oxide thereof, or a pharmaceutical composition comprising the same, and the use of the compound in (i) preparing an acetaldehyde dehydrogenase 2 (ALDH2) agonist and / or (ii) preparing a drug for treating or preventing alcohol-related diseases and / or diseases capable of being treated or prevented by promoting the metabolism of acetaldehyde or other aldehydes; wherein the compound is shown as formula A.

The application discloses a high-activity acetaldehyde dehydrogenase mutant, a preparation method and application thereof. The mutant is obtained by rational design on acetaldehyde dehydrogenase ALDHTt from thermophilic thermus, and is specifically that an asparagine at the 159th position is mutated into tyrosine, and is recorded as N159Y. Enzymatic property characterization shows that the specific enzyme activity of the mutant N159Y is 2.08 times of that of the wild type, the catalytic efficiency is 5.3 times of that of the wild type, and is 2.96 times of that of human ALDH2. Molecular dynamics simulation reveals that the flexibility of the mutant is moderately enhanced in the vicinity of the substrate binding channel and the cofactor binding site, which is beneficial to reduce the substrate entry energy barrier and promote the cofactor binding and release, and meanwhile, the overall structural stability is not adversely affected. The mutant overcomes the defects of human ALDH2, such as difficult expression and poor stability, and can be used as a core enzyme element for constructing an alcohol metabolism multi-enzyme cascade system or an oral enzyme preparation, and has a wide application prospect in preparation of products for alcohol metabolism or acetaldehyde clearance.

The invention discloses a method for directionally enriching and screening peptide fragments capable of effectively promoting the activity of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) from complex biological enzymatic hydrolysate, and belongs to the field of biotechnology and active peptide screening. The method comprises the following steps: co-immobilizing ADH1B and ALDH2 on the same solid-phase carrier in a high-activity manner by adopting a segmented pH sequential coupling technology to prepare a dual-enzyme affinity carrier; the carrier is used for adsorbing peptide fragments capable of being specifically combined with double enzymes in a complex peptide library; step-by-step elution is carried out by utilizing a specific competitor of ADH1B and ALDH2, so that two types of targeted peptide enriched components are respectively obtained; the specificity is verified through reverse screening and alcohol metabolism enzyme activity promotion function determination. According to the invention, high-efficiency parallel screening and synergistic combination discovery of alcohol metabolism key pathway double-target active peptides are realized for the first time, and an innovative technical platform is provided for developing a multi-target and high-efficiency alcohol metabolism regulator.

The disclosure is directed to, in part, compounds, or pharmaceutically acceptable salts or solvates thereof, for modulating the activity of aldehyde dehydrogenase such as ALDH2 and / or methods for treating and / or preventing an alcohol related disorder such as alcohol use disorder, alcohol induced disorder, alcohol abuse, alcohol dependence, alcohol intoxication, alcohol withdrawal, and the like and / or methods for reducing the amount of alcohol consumed, reducing alcoholic cravings, or increasing the percentage of no heavy drinking days for a subject with alcohol use disorder.

The invention discloses a nitrate drug metabolic enzyme activity quantitative detection method in the technical field of drug metabolism and individualized medication, which comprises the following steps: incubating a reaction system containing theophylline acetaldehyde or a hydrate thereof with whole blood of an individual to be detected, and detecting the amount of theophylline acetic acid generated by the theophylline acetaldehyde through specific metabolism of ALDH1A1 and ALDH2 in the system by adopting LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry); the metabolic clearance ability is assessed based on the amount of production. Whole blood is used as an enzyme source, blood cells do not need to be separated, the process is simple and convenient, the actual activity of in-vivo related enzymes can be directly and quantitatively reflected, the limitation of traditional genotype detection is overcome, clinical medication of nitrate drugs can be accurately guided, and drug failure and tolerance risks can be predicted.

The invention belongs to the technical field of biological medicine detection, and provides a fluorescent probe as well as a preparation method and application thereof. The fluorescent probe disclosed by the invention can emit relatively weak fluorescence and also can specifically and rapidly react with the ALDH2 enzyme to generate a product with strong fluorescence, and the fluorescence intensity is positively correlated with the concentration of the ALDH2 enzyme. The fluorescent probe has the beneficial effects that (1) the fluorescent probe used for detecting the enzyme activity of ALDH2 is good in molecular stability and can be stored and used for a long time; and (2) the fluorescent signal brightness is high, the detection signal-to-noise ratio is high, and the sensitivity is good. (3) the selectivity is excellent, and ALDH2 enzyme can be specifically detected in a complex biological sample. And (4) good biological membrane permeability is achieved, so that the method can be used for detecting the enzyme activity of ALDH2 in living cells. And (5) the detection speed is high. And (6) the detection response is sensitive, and the signal intensity can be enhanced along with the increase of the ALDH2 enzyme content in the species to be detected.